

# Syncom Formulations (India) Limited



A WHO-GMP & ISO 9001:2000 Certified Company  
CIN L24239MH1988PLC047759

SYNCOM/SE/2016

30<sup>th</sup> July, 2016

[online filing at listing.bseindia.com](http://online.filing.at.listing.bseindia.com)

To,  
The General Manager  
DCS-CRD  
BSE Ltd.  
Dalal Street, Fort,  
MUMBAI-400001

**BSE CODE: 524470**

**Subject: Submission of the Standalone Unaudited Financial Results for the Quarter ended 30th June, 2016 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir,

This has in continuation of our letter No. SYNCOM/SE/2016 dated 21<sup>st</sup> July, 2016 regarding information for Board meeting for consideration and approval of the Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2016.

We are pleased to submit the Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2016 which was considered and approved by the Board at their Meeting held on the 30<sup>th</sup> July, 2016 in accordance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above results being given for publication in the English and Marathi Newspapers.

You are requested to take on records the above said financial results for your reference and record.

Thanking You,  
Yours Faithfully,

**FOR SYNCOM FORMULATIONS (INDIA) LTD.**



**NAFISA VAKIL**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**

Encl.: a/a

*Bringing a smile on every face...*



# SYNCOM FORMULATIONS (INDIA) LTD.

Regd. Off.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI - 400 093

Works : 256-257, Sector - 1, Pithampur (Dhar), E-mail : info@sfil.in, www.sfil.in

CIN : L24239MH1988PLC047759

## UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> JUNE, 2016

₹ IN LACS

Sr. No.	PARTICULARS	Quarter Ended			Year Ended
		30.06.2016 (Unaudited)	31.03.2016 *(Audited)	30.06.2015 (Unaudited)	31.03.2016 (Audited)
01	(a) Net Income From Operations (Net of excise duty)	4282.61	4731.36	3932.46	18190.48
	(b) Other Operating Income	66.77	54.40	71.31	199.22
02	Expenses	4349.38	4785.76	4003.77	18389.70
	(a) Cost of Materials consumed	1660.95	819.39	2137.06	6890.03
	(b) Purchase of stock in trade	848.04	2955.06	771.58	6630.17
	(c) Changes in inventories	482.73	(282.50)	(153.79)	(365.04)
	(d) Employee benefits expenses	360.45	375.78	335.01	1361.37
	(e) Depreciation and amortization expenses	85.00	44.81	85.00	299.81
	(f) Other expenses	612.44	593.87	569.96	2212.82
	Total Expenses	4049.61	4506.41	3744.82	17029.16
03	Profit/(Loss) from Operations before other (1-2) income, finance costs and exceptional items	299.77	279.35	258.95	1360.54
04	Other Income	85.12	102.35	24.64	266.83
05	Profit/(Loss) from Ordinary activities before finance costs and exceptional items (3+4)	384.89	381.70	283.59	1627.37
06	Interest & Financial Charges	6.90	2.09	2.05	7.09
07	Operating Profit after interest & exceptional items(5-6)	377.99	379.61	281.54	1620.28
08	Exceptional Items	0.00	0.00	0.00	0.00
09	Profit/(Loss) from Ordinary activities before tax	377.99	379.61	281.54	1620.28
10	Tax expenses	125.00	144.23	56.50	574.53
11	Net Profit(+)/Loss(-)from ordinary activities after tax(9-10)	252.99	235.38	225.04	1045.75
12	Extraordinary items (net of tax expenses)	0.00	10.19	0.00	10.19
13	Net Profit(+)/Loss(-) for the period (11+12)	252.99	225.19	225.04	1035.56
14	Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00
15	Minority interest	0.00	0.00	0.00	0.00
16	Net Profit/(Loss) after taxes, minority interest & share of profit/loss of associates (13+14+15)	252.99	225.19	225.04	1035.56
17	Paid-up equity Share Capital (Equity share of Rs. 1 each)	7806.52	7806.52	7806.52	7806.52
18	Reserves (excluding Revaluation Reserves)	-	-	-	3063.44
19	(I) Earning Per Share (EPS) before extraordinary items (in 1/- each) (not annualised)				
	a) Basic Earning per share	0.03	0.03	0.03	0.13
	b) Diluted Earning Per Share	0.03	0.03	0.03	0.13
19	(II) Earning Per Share (EPS) (after extraordinary items (in 1/- each) (not annualised)				
	a) Basic Earning per share	0.03	0.03	0.03	0.13
	b) Diluted Earning Per Share	0.03	0.03	0.03	0.13

### Notes :

- The above financial results were reviewed and approved by the Audit Committee and the Board of Directors at their meeting held on 30th July 2016.
- The limited review under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors. The report does not contain anything which would have an impact on the results for the year ended 30th June 2016.
- Figures for the previous periods/year have been regrouped wherever necessary.
- The company is operating in single segment till 30th June'2016 the company was dealing only in one segment relating to pharmaceuticals, however the board considered to have two more segment of business activities relating to (1) Renting of Property (2) Trading, Dealing, Import & Export in all type of commodities.
- \*The figures of quarter ended 31.03.2016 are the balancing figures between audited figures in respect of the full financial year & the published year to date figures upto the 3rd quarter of that financial year.

By order of the Board of Directors  
For Syncom Formulations (I) Ltd.

KEDARMAL BANKDA  
Chairman & Wholetime Director

Place : Indore

